09.01.10
Less than a month after expanding its manufacturing capacity (see Industry News, page 69), executives at the Perkasie, Pa.-based biomedical textiles manufacturer added to its management team. In a formal news release, officials announced the hiring of Kenneth Ross as business development director, Tony J. Troiano as Lean “champion” and Joan M. Anthony as marketing manager.
In his new position, Ross will handle accounts in the soft tissue and general surgery device market. He joined Secant from Dew Technologies Inc., a Fairborn, Ohio-based implant manufacturer that was acquired by TriMas Corporation in August 2007. Executives with TriMas—a Bloomfield Hills, Mich.-based manufacturer of spinal and trauma implant products—expected the merger to give the firm access to new markets.
Ross spent seven years in senior-level positions at Dew Technologies. Prior to that, he worked for Architects Associated Inc., a Dayton, Ohio-based full-service architectural firm, and DePuy Orthopedics Inc. (a Johnson & Johnson company) in Warsaw, Ind.
Troiano has more than a decade of experience in manufacturing and transactional continuous improvement, manufacturing operations, and product and process design in various organizations. He was a project manager at The Vanguard Group, an investment management company; and an engineer for Whirlpool Corporation.
Secant officials hired Troiano to develop and implement a Lean manufacturing program at the company. He spearheaded such projects at the Delaware Valley Industrial Resource Center in Philadelphia, Pa., and Samsung Electronics.
As marketing manager, Anthony will supervise all marketing, communications, and business development support programs. She spent more than a decade with Hewlett-Packard Company gaining experience in marketing programs management, product marketing, integrated marketing communications, customer relationship management, direct and web marketing, and closed-loop demand generation.
Secant’s recent expansion efforts are part of the company’s long-term strategy to tap into the lucrative tissue engineering market. Industry experts predict the total market for tissue engineering—including heart valve repair and replacement; musculosketetal bone and ligament repair and replacement; and urologic bladder slings—will surpass $11.5 billion by 2016.
In his new position, Ross will handle accounts in the soft tissue and general surgery device market. He joined Secant from Dew Technologies Inc., a Fairborn, Ohio-based implant manufacturer that was acquired by TriMas Corporation in August 2007. Executives with TriMas—a Bloomfield Hills, Mich.-based manufacturer of spinal and trauma implant products—expected the merger to give the firm access to new markets.
Ross spent seven years in senior-level positions at Dew Technologies. Prior to that, he worked for Architects Associated Inc., a Dayton, Ohio-based full-service architectural firm, and DePuy Orthopedics Inc. (a Johnson & Johnson company) in Warsaw, Ind.
Troiano has more than a decade of experience in manufacturing and transactional continuous improvement, manufacturing operations, and product and process design in various organizations. He was a project manager at The Vanguard Group, an investment management company; and an engineer for Whirlpool Corporation.
Secant officials hired Troiano to develop and implement a Lean manufacturing program at the company. He spearheaded such projects at the Delaware Valley Industrial Resource Center in Philadelphia, Pa., and Samsung Electronics.
As marketing manager, Anthony will supervise all marketing, communications, and business development support programs. She spent more than a decade with Hewlett-Packard Company gaining experience in marketing programs management, product marketing, integrated marketing communications, customer relationship management, direct and web marketing, and closed-loop demand generation.
Secant’s recent expansion efforts are part of the company’s long-term strategy to tap into the lucrative tissue engineering market. Industry experts predict the total market for tissue engineering—including heart valve repair and replacement; musculosketetal bone and ligament repair and replacement; and urologic bladder slings—will surpass $11.5 billion by 2016.